Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
Launched by ASTRAZENECA · Jan 26, 2015
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
The study is an observational multicenter descriptive study. It is planned to enroll approximately 1000 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site.
This is an observational study, so there is no treatment protocol or subjects' management recommendations required. The study subjects receive medical treatment according to the ro...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent . Men and women at least 40 years old, with smoking history more than 10 pack-years.
- • Hospitalization for the reason of COPD exacerbation (exacerbation defined as acute condition, different from typical fluctuations of general condition and requiring change of therapy).
- • Diagnosis of severe or very severe COPD based on final spirometry (performed in a standardized manner using salbutamol 400 mg), or history of diagnosis of severe or very severe COPD based on spirometry performed during 6 months before the hospitalization.
- Exclusion Criteria:
- • Participation in any interventional study.
- • Concomitant respiratory diseases, i.e. confirmed or suspected malignancy or any other serious condition, including lung tumor, lung fibrosis, interstitial lung disease, tuberculosis, sarcoidosis.
- • Patient is unable or unwilling to complete questionnaires, unable to understand study procedures, or other reasons which, in the investigator's opinion, could affect study procedures performance.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
St.Petersburg, , Russian Federation
Ekaterinburg, , Russian Federation
Kazan, , Russian Federation
Krasnodar, , Russian Federation
Yaroslavl, , Russian Federation
Rostov On Don, , Russian Federation
Smolensk, , Russian Federation
Kemerovo, , Russian Federation
Krasnoyarsk, , Russian Federation
Novosibirsk, , Russian Federation
Ryazan, , Russian Federation
Moscow, , Russian Federation
Barnaul, , Russian Federation
Omsk, , Russian Federation
Izhevsk, , Russian Federation
Ufa, , Russian Federation
Chelyabinsk, , Russian Federation
Kursk, , Russian Federation
Petrozavodsk, , Russian Federation
Chita, , Russian Federation
Yakutsk, , Russian Federation
Orel, , Russian Federation
Kirov, , Russian Federation
Seversk, , Russian Federation
Gatchina, , Russian Federation
Voronez, , Russian Federation
Blagoveshchensk, , Russian Federation
Cherepovets, , Russian Federation
Naberezhnye Chelny, , Russian Federation
Novokuznetsk, , Russian Federation
Patients applied
Trial Officials
Alexander Bedenkov, Medical Director
Study Director
AstraZeneca
Sergey Avdeev, MD, PHD
Principal Investigator
Federal State Institution "Scientific Research Institute of Pulmonology" FMBA of Russia
Andrey Belevsky, PHD
Principal Investigator
Federal State Institution "Scientific Research Institute of Pulmonology" FMBA of Russia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials